Advertisement

Topics

Fix Antibiotic Payment Models To Spur R&D Investment, US FDA’s Gottlieb Says

14:15 EDT 14 Sep 2018 | SCRIP

Citing need for more ‘pull’ incentives to overcome commercial hurdles, FDA commissioner says a subscription-based fee reimbursement system would provide...

      

Related Stories

 

Original Article: Fix Antibiotic Payment Models To Spur R&D Investment, US FDA’s Gottlieb Says

NEXT ARTICLE

More From BioPortfolio on "Fix Antibiotic Payment Models To Spur R&D Investment, US FDA’s Gottlieb Says"

Advertisement
Quick Search
Advertisement
Advertisement